|
Home | Medical-Newswire.Com:
|
(EMAILWIRE.COM, May 07, 2012 ) New York, NY -- European elections, the people's protests of Putin in Russia and Disney's (DIS) 'The Avengers' dominated headlines over the weekend. As the Russian people displayed their dismay with the re-election of Vladimir Putin in Russia, France's Nicolas Sarkozy was the latest European politician to receive the boot from voters still feeling the pain of the global economic meltdown a few years ago - and incumbents in Greece didn't fare much better.
While that all put pressure on the recoveries in those respective regions, The Avengers turned into quite the feel-good success story for Disney, as Earth's Mightiest Heroes stormed big screens around the world in record-setting fashion - which gives us a pretty good indication that consumers are still willing to spend on play and leisure time, as long as they believe that the time will be worth it.
On the other side of the coin it looks like the financial headlines are preparing investors for another broad pullback.
Dendreon (DNDN): Dendreon (DNDN) is set to report earnings on Monday. Shares collapsed last summer when the company completely revamped its sales and earnings targets for the prostate cancer immunotherapy treatment Provenge due to pricing and reimbursement concerns, but as sales numbers started to recover and investors regained confidence in the potential of the treatment, DNDN shares spiked to their current levels of over eleven dollars.
Analysts are generally expecting double the Provenge sales of the same quarter for last year, and any surprises could spark a modest rally.
With the earnings news pending, DNDN will be a stock to watch this week. This one is also showing up on numerous radars as a potential buyout candidate, especially with mergers and acquisitions picking up steam in the sector of late.
FuelCell Energy (FCEL): Shares of FuelCell Energy (FCEL) were tearing it up earlier this year on news of a significant foreign investment and the unfolding of other key developments, but had since pulled back when the hype ceded and the market as whole started to stutter.
The company announced last week that it had completed the deal with South Korea's POSCO Energy, which brings $30 million to the FCEL cash coffers and adds to growing cash reserves that were also recently strengthened by a stock offering.
The POSCO Energy collaboration is also expected to expand as the year goes on and the cash raised from both of these events fits into CEO Chip Bottone's growth strategy, which includes potential larger deals in the United States.
"The public offering of stock in March combined with this capital raise from our partner, POSCO Energy, are an important part of our growth strategy. Strengthening our balance sheet is meaningful to prospective customers looking to enter into long term relationships with us and the stronger cash position is expected to enable larger projects here in the United States," noted Mr. Bottone in a press release issued last week.
Synergy Pharmaceuticals (SGYP): After flying higher over the past couple of months on the potential of the company's flagship product, Plecanatide for the treatment of chronic idiopathic constipation and constipation-predominant irritable bowel syndrome, positive reports by numerous analysts, and an FDA setback for a competing company, shares of Synergy Pharmaceuticals (SGYP) came back to earth late last week on the announcement of a stock offering that was priced at $4.50.
While the company took advantage of the recent price run to land a more favorable financing deal, the cash infusion may also strengthen Synergy's position as a potential buyout candidate as big players such as Pfizer (PFE) are flush with cash and possibly looking to make a few moves in order to boost pipelines depleted by popular drugs coming off patent.
Investors may see this pullback as another opportunity to take a chance on Plecanatide, which to this point has demonstrated a superior side effect profile than its potential competition. Additionally, Synergy should now have enough cash to carry through until the results are released from the ongoing Phase II/III trial, expected later this year.
Given the early-year runup and the pullback on the stock offering, Synergy remains a stock to watch.
For full version of this week's 'Weekly Stock Watch' visit:
http://vfcsstockhouse.com/blog/article/-weekly-stock-watch-dndn-dis-fcel-sgyp-imuc-imsc-siga-hgsi-cpst-gsk-gltc-tlon-bvti
At the conclusion of each week, VFC's Stock House, an information and research outlet that brings ideas and opens discussions to a broad spectrum of investors, examines some news items, stocks and stories that made headlines during the previous trading week, but may also make headlines or influence trends during the upcoming week as well. Although focusing intently on the biotech and healthcare sectors, due attention is also given to potential market-moving or game-changing companies in a broad variety of markets and industries. The 'Weekly Stock Watch' will also introduce new companies for coverage and identify some stocks that may have entered 'buy territory'.
Follow VFC's Stock House on Twitter: https://twitter.com/#!/VFCsStockHouse
'Like' VFC's Stock House on Facebook: http://www.facebook.com/pages/VFCs-Stock-House/143724412345213
About VFCsStockHouse.com:
VFC's Stock House is an information and research outlet that brings new ideas to the table and opens discussions for a broad spectrum of investors, with a strong focus on - but not limited to - biotech stocks and the pharmaceutical and healthcare sectors. VFC's Stock House provides individual company profiles, write-ups and reports as well as giving general insights into broader-market news through various 'Stock Watch' lists. At the conclusion of most weeks, VFC's Stock House issues a "Weekly Stock Watch" that examines news items, stocks and stories that made headlines during the previous trading week, but may also make headlines or influence trends during the upcoming week as well. The information contained within the pages of VFC’s Stock House are not intended to be taken as advice, but as a starting point where investors can follow up with their own DD and devise their own entry and exit strategies.
The goal of VFC's Stock House is to bring new ideas, companies and discussions to investors and readers. With respect to the increased amount of time necessary to maintain quality, VFC's Stock House is at times compensated from third parties to research and cover certain companies that fit the profile of what interests the readers of VFC's Stock House. While taking compensation poses as an inherent perception of bias in coverage, the ultimate goal is to bring ideas and information to the eyes of readers, who can then decide what is and what is not relevant.
For full disclaimer visit: http://vfcsstockhouse.com
VFC's Stock House
VFC
240-786-2111
vfc@vfcsstockhouse.com 
Source: EmailWire.com
|
|
|
|
